Form 4: Replimune Group CFO Emily Hill Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
Chief Financial Officer of Replimune Group, Emily Luisa Hill, reports the acquisition of common stock and stock options.
Summary
- Emily Luisa Hill, CFO of Replimune Group, filed a Form 4 detailing changes in beneficial ownership.
- On April 1, 2025, Hill acquired 45,000 shares of common stock through restricted stock units (RSUs).
- These RSUs vest over time, with 25% vesting on May 15, 2026, and the remainder vesting in three approximately equal annual installments until May 15, 2029, contingent upon continuous service.
- Hill also acquired an option to purchase 67,500 shares of common stock at an exercise price of $8.40 on April 1, 2025.
- 25% of the shares underlying the stock option vest on April 1, 2026, with the remainder vesting in 36 approximately equal monthly installments thereafter.
- Following these transactions, Hill directly owns 146,057 shares of Replimune Group common stock and options to purchase 67,500 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants to the CFO. While insider ownership is generally viewed positively, this is a routine disclosure.
Positives
- The acquisition of shares and stock options by the CFO could be interpreted as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules for the RSUs and stock options suggest a long-term commitment from the CFO.
Industry Context
This filing is a routine disclosure related to executive compensation and ownership. It doesn't provide specific insights into Replimune's competitive position or broader industry trends.
Stakeholder Impact
- The increased ownership stake of a key executive could positively influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of earliest transaction: Acquisition of common stock and stock options. |
| 04/01/2025 | Date of stock option grant. |
| 04/03/2025 | Date of Form 4 filing. |
| 04/01/2026 | 25% of the shares underlying this stock option vest. |
| 05/15/2026 | 25% of the RSUs will vest. |
| 05/15/2029 | Final vesting date for RSUs. |
| 04/01/2035 | Expiration date of stock option. |
Keywords
Replimune Group, Emily Hill, CFO, Form 4, Beneficial Ownership, Stock Options, RSUs, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.